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ABSTRACT
Exosomes are nanosize vesicles released from cancer cells containing microRNAs 
that can influence gene expression in target cells. Curcumin has been shown to exhibit 
antitumor activities in a wide spectrum of human cancer. The addition of Curcumin, 
to Chronic Myelogenous Leukemia (CML) cells, caused a dose-dependent increase 
of PTEN, target of miR-21. Curcumin treatment also decreased AKT phosphorylation 
and VEGF expression and release. Colony formation assays indicated that Curcumin 
affects the survival of CML cells. Some observation suggest a possible cellular disposal 
of miRNAs by exosomes. To elucidate if Curcumin caused a decrease of miR-21 in 
CML cells and its packaging in exosomes, we analyzed miR-21 content in K562 and 
LAMA84 cells and exosomes, after treatment with Curcumin. Furthermore, we showed 
that addition of Curcumin to CML cells caused a downregulation of Bcr-Abl expression 
through the cellular increase of miR-196b.
The effects of Curcumin was then investigated on a CML xenograft in SCID mice. 
We observed that animals treated with Curcumin, developed smaller tumors compared 
to mice control. Real time PCR analysis showed that exosomes, released in the plasma 
of the Curcumin-treated mice, were enriched in miR-21 with respect control. Taken 
together, our results suggested that a selective packaging of miR-21 in exosomes 
may contribute to the antileukemic effect of Curcumin in CML.
BACKGROUND
Chronic myeloid leukemia (CML) is characterized 
by the clonal expansion of myeloid precursors. The t(9;22)
(q34.1;q11.21) translocation, occurring in approximately 
95% of all CML patients, is considered the hallmark of 
CML and generates the chimeric BCR-ABL gene [1].
The Bcr-Abl oncoprotein constitutively activates 
several downstream pathways, responsible for the 
induction of cellular proliferation, loss of adhesion, 
blockage of cellular differentiation, and inhibition of 
programmed cell death [2, 3]. Exosomes are nanosize 
vesicles of endocytic origin that are released by most 
cell types when multivesicular bodies (MVBs) fuse 
with the plasma membrane [4]. Originally described as 
vesicles to discard transferrin receptor in erythrocytes 
differentiation [5], exosomes are now considered as 
molecular messengers with the potential to modulate 
intercellular communication and tumor microenvironment 
[6], promoting angiogenesis [7], tumor development 
and formation of metastasis [8]. Several reports suggest 
WKDWH[RVRPHVFRQWDLQPL51$VWKDWFDQLQÀXHQFHJHQH
expression in target cells thus modulating their behavior. 
0ROHFXODUSUR¿OLQJDQDO\VHVKDYHUHYHDOHGWKDWH[RVRPHV
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of different cellular origin contain a unique expression 
SUR¿OHRIP51$VDQGPL51$VZKLFKPD\GLIIHUIURP
the signatures of their parent cells. MiRNAs with tumor-
suppressor function are often lost in cancer [9], moreover 
it has been demonstrated a possible cellular disposal role 
of miRNAs by exosomes [10]. In our previous paper, 
we showed that exosomes released by CML cell lines 
such as LAMA84 cells transport miRNAs. In particular, 
we demonstrated that miR-126 shuttled by exosomes is 
biologically active in target cells and modulates tumor-
endothelial crosstalk occurring in the bone marrow 
microenvironment [6, 7].
Polyphenols such as Curcuminoids affect the 
expression of miRNAs, both in vitro and in vivo [11]. 
Curcumin (diferuloylmethane) the main active polyphenol 
extracted from the rhizomes of turmeric (Curcuma 
longa) inhibits cell proliferation, invasion, migration, 
DQJLRJHQHVLV DQG LQÀDPPDWLRQ DQG LQGXFHV FHOO F\FOH
arrest and apoptosis in several cancers [12, 13]. Target 
analysis of miRNA expression revealed that Curcumin 
down-regulates the expression of pro-oncogenic 
miR-17-5p, miR-20a, miR-21, and miR-27a in human 
colo-rectal carcinoma cell lines. This miRNA expression 
SUR¿OHZDVDVVRFLDWHGZLWKLQFUHDVHGDSRSWRVLVGHFUHDVHG
cell proliferation, and tumor invasion in vitro [14, 15]. 
Mudduluru et al [15] showed that Curcumin suppresses 
tumor growth and metastasis in colorectal cancer through 
downregulation of miR-21, a microRNA often found 
RYHUH[SUHVVHGLQVHYHUDOFDQFHUV'LÀXRULQDWHG&XUFXPLQ
(CDF), a nontoxic analog of the dietary ingredient 
Curcumin has been shown to modulate the expression of 
miR-21 and PTEN in pancreatic cancer [16].
MiR-21 regulates tumor growth, invasion and 
metastasis by targeting multiple tumor suppressor genes 
such as PTEN [17]. PTEN is one of the most frequently 
mutated or silenced tumor suppressors in human cancer; 
PTEN antagonizes the PI3K-AKT pathway [18] and is 
known to modulate VEGF mediated angiogenesis via the 
down-regulation of the PI3K/AKT pathway in many solid 
tumors [19]. Studies have shown that PI3K/AKT signaling 
pathway is activated in numerous leukemia cell lines and 
myeloid leukemia patients together with a decrease in the 
expression of PTEN gene and/or protein [20]. PTEN has 
a critical role in the pathogenesis of BCR-ABL-mediated 
leukemogenesis and myeloproliferative disorders [21].
MiR-196b is another microRNA, closely associated 
with leukaemia. It has been shown that miR-196b 
was downregulated in EB-3 cells and in patients with 
B-cell acute lymphocytic leukaemia (ALL). In contrast, 
miR-196b was found over-expressed in patients with acute 
myeloid leukaemia (AML) [22]. Little is known on the 
role of miR-196b in CML. The expression of miR-196b 
is lower in CML patients than in healthy individuals. 
Interestingly, using a bioinformatic approach, Bcr-Abl has 
EHHQLGHQWL¿HGDVWDUJHWRIPL5EDQGORZH[SUHVVLRQ
levels of miR-196b, were correlated with up-regulation of 
the oncogene BCR-ABL1 [23].
Curcumin is a promising compound that in 
association with classical tyrosine kinase inhibitor, 
may improve the treatment of CML patients resistant 
to Imatinib, the election drug for this leukemia [24]. 
In this study, we show in in vitro and in vivo models that 
treatment of CML cells with Curcumin caused a miR-21-
mediated modulation of PTEN/AKT pathway leading to 
the inhibition of leukemic cell growth. On the other hand, 
Curcumin induced the up-regulation of miR-196b and a 
decrease of BCR-ABL at mRNA and protein level.
We suggest that in CML, Curcumin probably 
acts through an enhanced disposal of miR-21 in 
exosomes and that this mechanism may contribute to the 
antileukemic effect.
MATERIALS AND METHODS
Cell culture and reagents
K562 and LAMA84 (DMSZ, Braunschweig, 
Germany) chronic myelogenous leukemia cells, were 
cultured in RPMI 1640 medium (Euroclone, UK) 
supplemented with 10% fetal bovine serum 
(Euroclone, UK), 2 mM L-glutamine, 100 U/ml penicillin 
and 100 mg/ml streptomycin (Euroclone, UK). All other 
reagents were purchased from Sigma (St. Louis, MO, 
USA), if not otherwise cited. In some experiments K562 
DQG/$0$FHOOVZHUHWUHDWHGZLWKȝ0*:D
VSHFL¿FQHXWUDOVSKLQJRP\HOLQDVHLQKLELWRUDOVRNQRZQ
as an inhibitor of exosomes release [25].
Proliferation assay (MTT assay)
Methyl-thiazol-tetrazolium (MTT) assay was done 
as previously described [26]; cells were plated in triplicate 
at 2 × 105SHUZHOODQGWUHDWHGZLWK&XUFXPLQ±ȝ0
for 24 hours. Means and standard deviations generated 
from three independent experiments are reported as the 
percentage of viable cells.
Exosomes isolation
Exosomes released by K562 and LAMA84 cells 
WUHDWHGRUQRWZLWK&XUFXPLQ DQGȝ0GXULQJ
a 24 h culture period, were isolated from culture 
medium supplemented with 10% FBS (previously 
ultracentrifuged) by different centrifugations as 
previously described [7, 27] and isolated vesicles 
ZHUHSXUL¿HGRQDVXFURVH'2FXVKLRQ9HVLFOHV
contained in the sucrose cushion were recovered, 
washed, and ultracentrifuged for 90 min in PBS 
and collected for use. Exosome protein content was 
determined with the Bradford method.
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Dynamic light scattering (DLS) analysis
Exosome size distribution was determined by DLS 
experiments. Exosome samples were diluted 30 times 
to avoid inter-particle interaction and placed at 20°C 
in a thermostated cell compartment of a Brookhaven 
Instruments BI200-SM goniometer, equipped with a 
solid-state laser tuned at 532 nm. Scattered intensity 
autocorrelation functions g2(t) were measured by using a 
Brookhaven BI-9000 correlator and analyzed in order to 
GHWHUPLQHWKHGLVWULEXWLRQ3'RIWKHGLIIXVLRQFRHI¿FLHQW
D by using a constrained regularization method or 
alternatively a gamma distribution. The size distribution, 
namely the distribution of hydrodynamic diameter Dh, was 
derived by using the Stokes-Einstein relation: D = (kBT)/
ʌȘ'KZKHUH'LVWKHGLIIXVLRQFRHI¿FLHQWN%LVWKH
%ROW]PDQFRQVWDQWȘ LV WKHPHGLXPYLVFRVLW\DQG7 LV
the temperature. The mean hydrodynamic diameter of 
H[RVRPHVZDVFDOFXODWHGE\¿WWLQJD*DXVVLDQIXQFWLRQWR
the measured size distribution.
Quantitative polymerase chain reaction (qPCR) 
for miRNAs and pre-miRNAs
The expression of miR-21 was tested by miScript 
PCR System (QIAGEN, Hilden, Germany). Total 
cellular RNA and miRNAs were isolated from K562 and 
LAMA84 cells and exosomes using the RNAspin Mini 
(GE Healthcare Science, Uppsala, Sweden). Reverse 
transcription reactions were performed using miScript II 
RT Kit (QIAGEN, Hilden, Germany) as described by the 
manufacturer’s instructions. We used miScript HiSpec 
Buffer for cDNA synthesis to detect mature miRNA and 
miScript HiFlex Buffer for cDNA synthesis to enable 
TXDQWL¿FDWLRQ RI SUHFXUVRU PL51$ 4XDQWLWDWLYH 5HDO
Time PCR was performed using miScript SYBR Green 
PCR Kit (QIAGEN, Hilden, Germany). Mature miR-21 
and miR-196b were detected by miScript Primer Assay 
and precursor miR-21 by miScript Precursor Assays 
according to manufacturer’s instructions. RNU6–2 was 
used as endogenous control. Expression levels of miRNAs 
and pre-miRNA were determined using the comparative 
Ct method to calculate changes in Ct and ultimately fold 
and percent change. An average Ct value for each RNA 
was obtained from triplicate reactions.
qPCR for PTEN, VEGF and BCR-ABL 
Total cellular RNA was isolated from K562 and 
LAMA84 cells and exosomes using the RNAspin Mini 
(GE Healthcare Science, Uppsala, Sweden). For PTEN, 
9(*)DQG%&5$%/P51$GHWHFWLRQȝJRIWRWDO51$
were reverse transcribed using the High Capacity cDNA 
Archive kit (Life Technologies, Carlsbad, California, U.S.), 
according to manufacturer’s instructions. PTEN, VEGF 
and BCR-ABL transcript levels were measured by TaqMan 
Real Time PCR, using TaqMan gene expression assay for 
PTEN (Hs00262123 m1), VEGF (Hs0090005.m1) and 
VEGF (Hs0090005.m1) (Life Technologies, Carlsbad, 
California, USA). Data were analyzed as previously 
described. Changes in the target mRNA content relative 
to GAPDH were determined using the comparative Ct 
method as described in the previous paragraph.
Transfection of K562 and LAMA84 cells with 
miR-21 mimic or inhibitor
Transfection of miScript miR-21 inhibitor 
(QIAGEN, Hilden, Germany) or miScript miR-21 
mimic in CML cells (QIAGEN, Hilden, Germany) was 
performed according Fast-Forward Transfection protocol 
(QIAGEN, Hilden, Germany). 6 × 104 K562 and LAMA84 
FHOOVSHUZHOOZHUHVHHGHGLQDZHOOSODWHLQȝORI
530,PL6FULSWPL5ƍ20HPL5RUPL6FULSW
PL5 PLPLF  ȝ0 ZHUH GLOXWHG LQ  ȝO FXOWXUH
PHGLXPZLWKRXW VHUXP WRREWDLQ D¿QDOQ0PL51$
concentration. The cells were transfected using HiPerFect 
Transfection Reagent (QIAGEN, Hilden, Germany) 
according to manufacturer’s instructions for 18 h. MiScript 
Inhibitor Negative Control (QIAGEN, Hilden, Germany) 
and AllStars Negative Control siRNA (QIAGEN, Hilden, 
Germany) were used as negative controls as indicated 
E\PDQXIDFWXUH¶V WHFKQLFDO VSHFL¿FDWLRQV 7UDQVIHFWLRQ
HI¿FLHQF\ZDVHYDOXDWHGE\TXDQWLWDWLYH5HDO7LPH3&5
Luciferase activity assay
7KHƍ875RI37(1FORQHGLQS(=;07YHFWRU
was obtained from Genecopoeia (Rockville, MD, USA). 
The constructs were designed based on the sequence 
of miR-21 binding sites. 12 × 104 K562 and LAMA84 
FHOOVSHUZHOO LQDZHOOSODWHZHUHVHHGHGLQȝO
of RPMI, the cells were transfected with 300 ng of the 
S(=;07 ¿UHÀ\ OXFLIHUDVH UHSRUW GLOXWHG LQ  ȝO
culture medium without serum. K562 and LAMA84 
cells were cotransfected with 6 pmol miR-21 mimic or 
miR-21 inhibitor using Attractene Transfection Reagent 
(QIAGEN, Hilden, Germany) according to manufacturer’s 
protocol. To test whether Curcumin treatment induces a 
modulation of miR-21 expression, thus inhibiting its 
target PTEN, K562 and LAMA84 cells were incubated 
ZLWK DQGȝ0RI&XUFXPLQ DIWHU WKH WUDQVIHFWLRQ
RI S(=;07 YHFWRUV )LUHÀ\ DQG 5HQLOOD /XFLIHUDVH
activities were measured consecutively using the kit Dual 
Glo® Luciferase Assay System (Promega Corp, Madison, 
WI, USA) 24 hours after transfection using GloMax®-
Multi Detection System (Promega Corp., Madison, WI, 
USA). Transfections were repeated for each samples, three 
times in duplicate. Normalized data were calculated as the 
UDWLRRI5HQLOOD)LUHÀ\/XFLIHUDVHDFWLYLWLHV
Oncotarget4www.impactjournals.com/oncotarget
ELISA for VEGF, AKT and pAKT
Conditioned medium (CM) of K562 and LAMA84 
FHOOVWUHDWHGZLWKȝ0&XUFXPLQWUDQVIHFWHG
or not with miR-21 mimic or inhibitor, was collected 
from cells after 24 hours of incubation. CM of K562 
DQG /$0$ FHOOV WUHDWHG ZLWK  ȝ0 *: RU
FRWUHDWHG ZLWK &XUFXPLQ DQG  ȝ0 *: ZHUH
also collected from cells after 24 h of incubation. CM 
aliquots were centrifuged to remove cellular debris and 
VEGF protein levels were measured using an ELISA kit 
(Invitrogen Carlsbad, California, USA), according to the 
manufacturer’s protocol.
.DQG/$0$FHOOVWUHDWHGZLWKȝ0
Curcumin, transfected or not with miR-21 mimic or 
inhibitor, were collected and lysated. K562 and LAMA84 
FHOOVWUHDWHGZLWKȝ0*:DQGRUFRWUHDWHGZLWK
&XUFXPLQDQGȝ0*:ZHUHDOVRFROOHFWHGDQG
lysated after 24 hours of incubation. pAKT levels were 
TXDQWL¿HG XVLQJ DQ (/,6$ NLW ,QYLWURJHQ &DUOVEDG
California, USA), according to the manufacture’s protocol. 
AKT1 (pS473) ultrasensitive ELISA allows to detect and 
quantify the level of AKT1 protein that is phosphorylated 
at serine residue 473. To normalize the sample for the 
total AKT1 amount, we used an AKT1 (total) ELISA kit 
(Invitrogen, Carlsbad, California, USA).
Western blot
Total cell lysates were subjected to SDS-PAGE 
electrophoresis and immunoblotting as previously 
described (26). Antibodies used in the experiments 
were: Alix, TSG 101, PTEN, AKT, pAKT, Bcr-Abl and 
actin (Cell Signaling Technology, Beverly, MA). K562 
or LAMA84 cells (5 × 106) were incubated with 20 
DQGȝ0&XUFXPLQRU'062IRUKRXUVQHJDWLYH
control). Samples were resolved in 6–8% SDSPAGE 
followed by immunoblotting.
Motility assay
K562 and LAMA84 cells treated or not with 20, 
ȝ0&XUFXPLQZHUHVXVSHQGHG LQ VHUXPIUHH530,
1640 medium supplemented with 0.1% BSA in transwells 
ZLWKȝPSRUH¿OWHUV DQG H[SRVHG WR FRPSOHWH530,
1640 as chemoattractant, for 24 hours. Some samples were 
FRWUHDWHGZLWKȝ0&XUFXPLQDQGȝ0*:
After incubation, cells migrated in the bottom wells were 
counted.
Colony formation assay
K562 or LAMA84 cells were plated in 6-well (2000/
ml/well) in Iscove’s-methicellulose medium (Methocult 
H4230, Stem Cell Technologies, Vancouver, Canada) 
FRQWDLQLQJRUQRW&XUFXPLQȝ0$IWHUGD\V
of culture, K562 and LAMA84 colonies were observed 
by phase-contrast microscopy and photographed. The area 
of ten colonies per condition were measured with the 
IMAGE-J software (http://rsbweb.nih.gov/ij/).
Ethics statement
All animal experiments were conducted in full 
compliance with University of Palermo and Italian 
Legislation for Animal Care.
CML mouse xenograft
0DOH 6&,' PLFH IRXUWR¿YH ZHHN ROG ZHUH
purchased from Charles River (Charles River Laboratories 
International, Inc., MA, USA) and acclimated for a week. 
0LFHUHFHLYHG¿OWHUHGZDWHUDQGVWHULOL]HGGLHWDGOLELWXP
Animals were observed daily and clinical signs were noted. 
0LFHZHUHUDQGRPO\DVVLJQHGWRVL[JURXSVRI¿YHHDFK
Each mouse was inoculated subcutaneously (sc) in the right 
ÀDQNZLWKYLDEOHVLQJOHFHOOVî7) suspended in 0.2 ml 
of PBS. Mice were treated every day, per os, for 2 weeks, 
with 2 mg of Curcumin or vehicle (corn oil) as control. 
No adverse reaction was observed in mice following 
administration of this dose of Curcumin or corn oil. One 
ZHHNDIWHUWKHODVWGD\RIWUHDWPHQWPLFHZHUHVDFUL¿FHG
tumors were removed and measured and exosomes were 
SXUL¿HGIURPSODVPD%ORRGZDVFROOHFWHGE\SRVWPRUWHP
cardiac puncture into blood collection tubes, centrifuged at 
850 × g for 20 min at 20°C and the supernatant (plasma) 
ZDVFROOHFWHG3ODVPDZDVFHQWULIXJHGDWJIRUƍDW
&DWJIRUƍ7XPRUYROXPHZDVGHWHUPLQHGE\
caliper using the formula: L × W2/2 = mm3 where L and 
W are the longest and shortest perpendicular measurements 
in millimeters, respectively. The tumor weights were 
calculated assuming that 1mm3 = 1mg.
RNA isolation from exosomes released in 
mice plasma
51$ IURP SUH¿OWHUHG SODVPD ZDV LVRODWHG ZLWK
exoRNeasy kit (Qiagen Hilden, Germany) according to 
the manufacturer’s protocol.The miR-21 levels were tested 
by miScript PCR System (QIAGEN, Hilden, Germany) 
IROORZLQJ H[WUDFWLRQ RI 51$ IURP  ȝO RI SODVPD
collected from mice treated with Curcumin and control 
mice, treated with vehicle (corn oil).
RESULTS
Characterization of exosomes released from 
K562 and LAMA84 cells after treatment 
with Curcumin
K562 and LAMA84 cells were treated with different 
FRQFHQWUDWLRQV ± ȝ0 RI &XUFXPLQ IRU  KRXUV
Cells viability was analyzed using the MTT assay. 
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7KHUHVXOWVLQGLFDWHGWKDWȝ0&XUFXPLQLQKLELWHGFHOO
proliferation (about 25%), as compared to cells treated 
with DMSO (0.001%), as control (Figure 1a and b). 
Nanovesicles released from K562 and LAMA84 cells 
WUHDWHGZLWK&XUFXPLQZHUHLVRODWHGSXUL¿HGRQDVXFURVH
gradient and characterized as exosomes, as we previously 
demonstrated [7]. Vesicles were analysed by Western 
EORWWLQJ )LJXUH F DQG G XVLQJ DQWLERGLHV VSHFL¿F
for Alix and TSG-101, well known exosomal markers. 
DLS (dynamic light scattering) analyses indicated that 
isolated exosomes had an average hydrodynamic diameter 
of about 100 nm, in agreement with data from other 
laboratories (Figure 1e).
Curcumin decreases miR-21 levels in CML cells
Curcumin treatment of K562 and LAMA84 cells 
produced, as demonstrated by real time quantitative 
assay, a 50% reduction of cellular miR-21, as compared 
to DMSO treated cells (Figure 2a and b). On the contrary, 
miR-21 was enriched in exosomes released by K562 
DQG/$0$FHOOVDIWHUWUHDWPHQWZLWKDQGȝ0
of Curcumin (Figure 2a and b). In order to investigate if 
Curcumin modulated the miR-21 expression or induced 
a selective packaging of miR-21 in exosomes, K562 and 
/$0$FHOOVZHUHFRWUHDWHGZLWK±ȝ0&XUFXPLQ
DQGȝ0RI*:DVSHFL¿FQHXWUDOVSKLQJRP\HOLQDVH
(nSMase) 2 inhibitor, also known as an inhibitor of 
exosomes release [25, 28]. As shown in Figure 2, GW4869 
induced an increase of miR-21 in K562 (Figure 2c) and 
LAMA84 (Figure 2d) cells compared with K562 and 
LAMA84 cells treated with Curcumin, the cotreatment 
with GW4869 and Curcumin partially reversed this effect. 
In order to exclude the possibility that Curcumin treatment 
of K562 and LAMA84 cells could directly affect miR-21 
expression, we measured, by Real Time PCR, the levels 
Figure 1: K562 a. and LAMA84 b. cell viability was measured by MTT assay after 24 h of treatment with Curcumin 
±±ȝ0The values were plotted as a percentage of viable cells. Each point represents the mean ± SD of three independent 
experiments, *p'HWHFWLRQRI$OL[DQG76*LQȝJRIH[RVRPHVSXUL¿HGIURPFRQGLWLRQHGPHGLXPRI.c. and LAMA84 
d.FHOOVWUHDWHGZLWK±ȝ0RI&XUFXPLQe. Dynamic light scattering (DLS) analysis of exosomes released by K562 and LAMA84 
FRQWUROíDQGWUHDWHGZLWKȝ0RI&XUFXPLQ
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of miR-21 precursor (pre-miR-21) in K562 and LAMA84 
cells. As shown in Figure 2, we found no statistically 
VLJQL¿FDQWGLIIHUHQFHRISUHPL5H[SUHVVLRQOHYHOLQ
K562 (Figure 2e) and LAMA84 cells (Figure 2f) in the 
different experimental conditions.
0L5WDUJHWV37(1ƍ875P51$
MiRNA target prediction algorithm indicates 
that PTEN is a predictive target of miR-21. Zhang et al 
showed that the inhibition of miR-21 and concomitant 
upregulation of PTEN mediates the anticancer activities 
RI&XUFXPLQ LQ16&/& FHOOV >@:H FRQ¿UPHG WKDW
PL5ELQGV WR37(1ƍ875P51$XVLQJ D)LUHÀ\
5HQLOOD 'XR/XFLIHUDVH UHSRUWHU YHFWRU S(=;07
ZKHUHWKHƍ875RI37(1ZDVFORQHGGRZQVWUHDPRIWKH
¿UHÀ\OXFLIHUDVHJHQH37(1S(=;:KHQ.FHOOV
transfected with reporter plasmid were incubated with 
DQGȝ0&XUFXPLQWKH¿UHÀ\OXFLIHUDVHDFWLYLW\ZDV
increased as compared with untreated cells (Figure 3a) 
WUDQVIHFWHGZLWK37(1S(=;'RZQUHJXODWLRQRIPL5 
by transfection of miR-21 inhibitor into K562 cells 
Figure 2: MiR-21 levels in K562 a. and LAMA84 b. cells and their released exosomes after treatment with 20 and 
ȝ0RI&XUFXPLQ for 24 hours and in their exosomes, were determined by quantitative Real time PCR analysis. 
MiR-21 levels in K562 c. and LAMA84 d. FHOOV WUHDWHGZLWKDQGȝ0RI&XUFXPLQDQGRU*:ȝ0 IRUKRXUVZHUH
determined by quantitative Real time PCR analysis. e.SUH0L5H[SUHVVLRQLQ.FHOOVWUHDWHGZLWKDQGȝ0RI&XUFXPLQIRU
24 hours, was determined by quantitative Real time PCR analysis. f. pre-MiR-21 expression in exosomes released by LAMA84 cells treated 
ZLWKDQGȝ0RI&XUFXPLQDQGRU*:ȝ0IRUKRXUVZDVGHWHUPLQHGE\TXDQWLWDWLYH5HDOWLPH3&5DQDO\VLV9DOXHVDUH
the mean ± SD of 3 independent experiments *pp
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FRQWDLQLQJ37(1S(=;LQFUHDVHGWKHDFWLYLW\RI¿UHÀ\
luciferase respect to untransfected K562 cells, similarly 
to Curcumin treatment. In contrast, luciferase activity 
GHFUHDVHGZKHQ.FHOOVFRQWDLQLQJ37(1S(=;ZHUH
transfected with miR-21 mimic.
,Q RUGHU WR FRQ¿UP WKH HIIHFW RI &XUFXPLQ RQ
decrease of miR-21 through its sorting in exosomes, we 
FRWUHDWHG. FHOOVZLWK  ȝ0*: DQG  DQG
 ȝ0 &XUFXPLQ$V VKRZHG LQ )LJXUH D *:
UHGXFHGWKHOXFLIHUDVHDFWLYLW\LQ37(1S(=;WUDQVIHFWHG
K562 cells compared with control cells. The cotreatment 
ZLWK  ȝ0 *: DQG  DQG  ȝ0 &XUFXPLQ
FDXVHGDQLQFUHDVHRIOXFLIHUDVHDFWLYLW\LQ37(1S(=;
WUDQVIHFWHG.)LJXUHDZLWKUHVSHFWWR37(1S(=;
transfected K562 cells treated with GW4869 alone. Similar 
results were obtained in LAMA84 cells (Figure 3b). These 
data indicate that Curcumin caused a decrease of miR-21, 
in K562 and LAMA84 cells, and consequently an increase 
of PTEN, its direct target.
Curcumin induces PTEN expression 
in CML cells
Previous results showed that also in our model, 
PL5WDUJHWVWKHƍ875RI37(1P51$5HDOWLPH
PCR analysis demonstrated that the addition of Curcumin, 
to CML cells, for 24 hours, caused a dose-dependent 
increase in PTEN mRNA (Figure 4a). PTEN mRNA levels 
increased of 2, 5 and 4 fold in K562 and LAMA84 cells 
IROORZLQJ WKH DGGLWLRQ RI  DQG ȝ0RI&XUFXPLQ
UHVSHFWLYHO\)LJXUHD'DWDZHUHFRQ¿UPHGDWSURWHLQ
level, by western blotting analysis; addition of Curcumin 
to CML cells, for 24 h, caused a dose-dependent increase 
in PTEN protein in K562 and LAMA84 cells lysate 
(Figure 4b). Densitometric analyses of corresponding 
western blots are showed in Figure S1a. In order to 
FRQ¿UPWKHHIIHFWRI&XUFXPLQRQWKHVRUWLQJRIPL5
LQH[RVRPHVZHFRWUHDWHG&0/FHOOVZLWKȝ0*:
DQGȝ0&XUFXPLQ$VVKRZHGLQ)LJXUHF*:
abrogated the upregulation of PTEN by Curcumin both 
LQ . DQG /$0$ FHOOV 'DWD ZHUH FRQ¿UPHG DW
protein level, by western blotting analysis (Figure 4e). 
Densitometric analyses of corresponding western blots 
are showed in Figure S1b. To further demonstrate the 
role of miR-21 in the modulation of PTEN levels we 
knocked down miR-21 in CML cells using the miR-21 
LQKLELWRU ƍ20HPL5 5HDO WLPH 3&5 DQDO\VLV
VKRZHG WKH WUDQVIHFWLRQ HI¿FLHQF\ RI PL5LQKLELWRU
in K562 and LAMA84 cells (Figure S1c). Inhibition of 
miR-21 in K562 and LAMA84 cells increased PTEN 
mRNA expression (Figure 4d). On the contrary, the 
addition of miR-21 mimic caused, as expected, a decrease 
of PTEN expression (Figure 4d). Real time PCR analysis 
VKRZHG WKH WUDQVIHFWLRQ HI¿FLHQF\ RI PL5 PLPLF
in K562 and LAMA84 cells (Figure S1c). In order to 
evaluate, in K562 and LAMA84 cells, if downregulation 
of PTEN expression in miR-21 mimic transfected 
cells was reverted after the addition of Curcumin, we 
treated the miR-21 mimic transfected CML cells with 
 ȝ0&XUFXPLQ$V VKRZQ LQ )LJXUH G EODFN EDUV
with white dots), Curcumin counteracted the effect of 
the transfection with miR-21 mimic, decreasing the 
expression of PTEN mRNA. On the contrary in K562 
and LAMA84 cells transfected with miR-21 inhibitor and 
treated with Curcumin, we observed a higher increase of 
PTEN mRNA expression than CML cells transfected with 
miR-21 inhibitor alone (Figure 4d, white bars).
Our data indicate that the Curcumin treatment 
induces an exosomes-mediated decrease of miR-21 that in 
turn causes the modulation of PTEN expression in CML 
FHOOVFRQ¿UPHGE\WKHVWXG\RIJDLQDQGORVVRIIXQFWLRQ
for miR-21.
Figure 3: Luciferase activity of K562 a. and LAMA84 b. cells transfected with reporter plasmid (PTEN-pEZX) and 
WUHDWHGZLWKDQGȝ0RI&XUFXPLQDQGRU*:ȝ0IRUKRXUV K562 (a) and LAMA84 (b) cells transfected with 
37(1S(=;ZHUHDOVRFRQWUDVIHFWHGZLWKPL5LQKLELWRURUPL5PLPLF9DOXHVDUHWKHPHDQ6'RILQGHSHQGHQWH[SHULPHQWV
*pp
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Curcumin modulates AKT phosphorylation 
in CML cells
It is documented that PTEN modulates the 
phosphatidylinositol 3-kinase (PI3K)/AKT signaling 
pathway, downregulating AKT phosphorylation.
To elucidate the effect of Curcumin treatment on 
AKT pathway in CML cells, we showed, by ELISA assay 
(Figure 5a and b) and western blot analyses (Figure S2a 
and S2b), that the addition of Curcumin, for 24 h, caused a 
dose-dependent decrease of AKT phosphorylation in CML 
cell. In order to support our hypothesis that the decrease 
of miR-21 was determined by a selective enrichment of 
this miRNA in CML exosomes, we treated leukemia cells 
ZLWK*:ȝ0)LJXUHDDQGEDQGWKLVWUHDWPHQW
caused an increase of AKT phosphorylation. Moreover 
WKHFRWUHDWHPHQWRI&0/FHOOVZLWK*:ȝ0DQG
&XUFXPLQ±ȝ0UHYHUWHG WKHHIIHFWVRI&XUFXPLQ
(Figure 5a and 5b). The role of miR-21 was further 
demonstrated by performing an ELISA assay of CML 
cells lysates, after transfection with an inhibitor or mimic 
of miR-21 (Figure 5c and 5d). MiR-21 expression was 
knocked down in CML cells using the miR-21 inhibitor 
ƍ20HPL5DVGHPRQVWUDWHGZLWKUHDO WLPH3&5
assay (Figure 1Sb). Inhibition of miR-21 in CML cells 
decreased the AKT phosphorylation similar to Curcumin 
treatment. On the contrary, the ELISA assay indicated 
that the overexpression of miR-21 in CML cells increased 
)LJXUHD37(1H[SUHVVLRQLQ.DQG/$0$FHOOVWUHDWHGIRUKRXUVZLWKDQGȝ0RI&XUFXPLQZDV
determined by quantitative Real time PCR analysis. b. Western blot analysis of PTEN in K562 and LAMA84 cells treated with 
DQGȝ0RI&XUFXPLQIRUKRXUV$FWLQZDVXVHGDVORDGLQJFRQWUROc. PTEN expression in K562 and LAMA84 cells treated 
ZLWKDQGȝ0RI&XUFXPLQDQGRU*:ȝ0IRUKRXUVZDVGHWHUPLQHGE\TXDQWLWDWLYH5HDOWLPH3&5DQDO\VLVd. PTEN 
H[SUHVVLRQLQ.DQG/$0$FHOOVWUDQVIHFWHGZLWKPL5PLPLFPL5LQKLELWRUWUHDWHGRUQRWZLWKȝ0&XUFXPLQRUVFUDPEOH
was determined by quantitative Real time PCR analysis. Values are the mean ± SD of 3 independent experiments *pp 
e.:HVWHUQEORWDQDO\VLVRI37(1LQ.DQG/$0$FHOOVWUHDWHGZLWKȝ0RI&XUFXPLQDQGRU*:ȝ0IRUKRXUV$FWLQ
was used as loading control.
Oncotarget9www.impactjournals.com/oncotarget
AKT phosphorylation (Figure 5c and 5d). Real time PCR 
DQDO\VLVVKRZVWKHRYHUH[SUHVVLRQHI¿FLHQF\RIPL5
in CML cells transfected with miR-21 mimic (Figure S1b). 
Our data indicate that the Curcumin treatment induces 
in CML cells, a dose-dependent regulation of AKT 
SKRVSKRU\ODWLRQFRQ¿UPHGE\WKHVWXG\RIJDLQDQGORVV
of function for miR-21.
Curcumin modulates VEGF expression 
in CML cells
A number of studies indicate that PTEN modulates 
the phosphatidylinositol 3-kinase (PI3K)/AKT signaling 
pathway and downregulates the expression of vascular 
endothelial growth factor (VEGF) (26). Real time PCR 
analysis demonstrated that the addition of Curcumin, 
to CML cells, for 24 hours, caused a dose-dependent 
decrease in VEGF mRNA (Figure 6). A 50% decrease 
of VEGF mRNA levels was observed in both K562 and 
/$0$FHOOVDIWHUWUHDWPHQWZLWKȝ0RI&XUFXPLQ
)LJXUHD7UDQVIHFWLRQRIPL5LQKLELWRUƍ20H
miR-21) in CML cells, caused a decrease of VEGF mRNA 
expression, similar to Curcumin treatment (Figure 6b), as 
demonstrated with real time PCR assay. The transfection 
of miR-21 mimic, antagonizing the induction of 
PTEN expression, increased VEGF mRNA expression 
(Figure 6b). In order to evaluate, in K562 and LAMA84 
cells, if the effects of the transfection with miR-21 mimic 
reverted after the addition of Curcumin, we treated 
WKHPL5PLPLF WUDQVIHFWHG&0/ FHOOVZLWK  ȝ0
Curcumin. As shown in Figure 6b (white bars), Curcumin 
counteracted the effect of the transfection with miR-21 
mimic, causing a decreased expression of VEGF mRNA. 
On the contrary in K562 and LAMA84 cells transfected 
with miR-21 inhibitor and treated with Curcumin, we 
observed a higher decrease of VEGF mRNA expression 
than CML cells transfected with miR-21 inhibitor alone 
(Figure 6b, white bars with black dots).
,Q RUGHU WR FRQ¿UP WKH HIIHFWV RI &XUFXPLQ RQ
VEGF protein release, we performed an ELISA assay on 
conditioned medium of K562 and LAMA84 cells treated 
ZLWK  DQG  ȝ0&XUFXPLQ IRU  K$V VKRZQ LQ
Figure 6 addition of Curcumin caused a dose-dependent 
decrease of VEGF released from CML cells (Figure 6c), 
we observed similar effects after transfection of miR-21 
inhibitor both in K562 and LAMA84 cells (Figure 6c). 
On the contrary, as shown in Figure 6c, the transfection 
of miR-21 mimic in K562 and LAMA84 cells, induces an 
)LJXUH$.7SKRVSKRU\ODWLRQDVVHVVHGE\(/,6$LQ.DDQG/$0$EFHOOVWUHDWHGZLWKDQGȝ0RI
&XUFXPLQDQGRU*:IRUKRXUVAKT phosphorylation, assessed by ELISA, in K562 c. and LAMA84 d. cells transfected 
ZLWKPL5PLPLFPL5LQKLELWRURUVFUDPEOHDQGRUWUHDWHGZLWKȝ0RI&XUFXPLQ9DOXHVDUHWKHPHDQ6'RILQGHSHQGHQW
experiments *pp.
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increase of secreted VEGF. The effects of the transfection 
with miR-21 mimic reverted after the treatment with 
Curcumin (Figure 6c, white bars), causing a decrease of 
VEGF release. On the contrary in K562 and LAMA84 
cells transfected with miR-21 inhibitor and treated with 
Curcumin, we observed a higher decrease of VEGF 
release than CML cells transfected with miR-21 inhibitor 
alone (Figure 6c, white bars with black dots).
In order to support our hypothesis that the decrease 
of miR-21 was determined by a selective enrichment 
of this miRNA in CML exosomes, we cotreated CML 
FHOOV ZLWK *:  ȝ0 DQG &XUFXPLQ ± ȝ0
As showed in Figure 6d, GW4869 abrogated the down 
regulation of VEGF by Curcumin both in K562 and 
LAMA84 cells.
Methocult assay
Methocult assay shows that K562 and LAMA84 
FHOOVWUHDWHGZLWK&XUFXPLQ±ȝ0IRUPFRORQLHV
in methylcellulose with a smaller area compared to 
control cells (Figure 7a). Colony formation assay was 
also performed with K562 and LAMA84 cells transfected 
with miR-21 mimic and inhibitor. As shown in Figure 7b, 
K562 and LAMA84 cells transfected with miR-21 mimic 
are able to form colonies greater compared to control cells. 
The transfection with miR-21 inhibitor caused a reduction 
of the colonies size respect to control cells, similarly to 
Curcumin treatment.
Curcumin reduces CML cells migration
Cell migration is a critical step for many biologic 
processes including leukemic blasts mobilization from 
bone marrow. We analyzed the effect of Curcumin 
DGGLWLRQ±ȝ0RQ.DQG/$0$FHOOVPRWLOLW\
Figure 7c shows that Curcumin treatment inhibited in 
a dose-dependent manner, the motility of K562 and 
LAMA84 cells towards complete medium. The treatment 
with GW4869 increases the motility of CML cells. 
7KHFRWUHDWPHQWZLWK±ȝ0RI&XUFXPLQDQGȝ0
GW4869 reverted the effect of Curcumin (Figure 7c). 
These results indicate that Curcumin affected K562 and 
LAMA84 cells migration.
)LJXUHD9(*)H[SUHVVLRQLQ.DQG/$0$FHOOVWUHDWHGZLWKDQGȝ0RI&XUFXPLQIRUKRXUVZDV
determined by quantitative Real time PCR analysis. b. VEGF expression in K562 and LAMA84 cells transfected with miR-21 
mimic, miR-21 inhibitor or scramble, was determined by quantitative Real time PCR analysis. c. VEGF protein level, assessed by ELISA, 
LQFRQGLWLRQHGPHGLXPRI.DQG/$0$FHOOVWUDQVIHFWHGZLWKPL5PLPLFPL5LQKLELWRUWUHDWHGRUQRWZLWKȝ0&XUFXPLQ
RUVFUDPEOHRUWUHDWHGZLWKDQGȝ0RI&XUFXPLQIRUKRXUVd. VEGF protein level assessed by ELISA, in K562 and LAMA84 
FHOOVWUHDWHGZLWKDQGȝ0RI&XUFXPLQDQGRU*:ȝ0IRUKRXUV9DOXHVDUHWKHPHDQ6'RILQGHSHQGHQWH[SHULPHQWV
*pp
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Curcumin inhibits Bcr-Abl expression in CML 
FHOOVE\LQFUHDVLQJPL5EOHYHOV
BCR–ABL is a constitutively active tyrosine kinase 
that triggers several downstream signaling pathways 
inducing the enhanced survival and proliferation of 
CML cells.
Real time PCR analysis demonstrated that 
Bcr-Abl mRNA levels decreased of about 20% and 45% 
LQ.FHOOVIROORZLQJWKHDGGLWLRQRIDQGȝ0RI
Curcumin, respectively (Figure 8a). Similar results were 
REWDLQHGLQ/$0$FHOOVWUHDWHGIRUKZLWKȝ0
RI&XUFXPLQ'DWDZHUHFRQ¿UPHGDWSURWHLQOHYHOE\
western blotting analysis. The addition of Curcumin to 
CML cells, for 24 h, caused a dose-dependent decrease of 
Bcr-Abl protein in K562 and LAMA84 cells (Figure 8b). 
In order to elucidate the molecular mechanism that causes 
Bcr-Abl decreased expression, we focused on miR-196b, 
a microRNA that targets Bcr-Abl. Curcumin treatment of 
K562 and LAMA84 cells caused, as demonstrated by real 
time quantitative assay, an increase of cellular miR-196b, 
as compared to DMSO treated cells. On the contrary, 
miR-196b was reduced in exosomes released by K562 
DQG/$0$FHOOVDIWHUWUHDWPHQWZLWKDQGȝ0
of Curcumin (Figure 8c and d). These data indicated that 
Curcumin increased miR-196b cellular levels leading to a 
reduction of Bcr-Abl protein amount in CML cells.
Anticancer effects of Curcumin in vivo
,Q RUGHU WR FRQ¿UP LQ DQ in vivo model, our 
in vitro results, we investigated the effects of Curcumin 
on a xenograft CML tumor model. K562 and LAMA84 
cells were inoculated subcutaneously in SCID mice and 
subsequently treated every day, for 2 weeks, with 2 mg 
of Curcumin or vehicle control (corn oil). One week 
DIWHU WKH ODVW GD\ RI WUHDWPHQW PLFH ZHUH VDFUL¿FHG
WXPRUVZHUHUHPRYHGDQGH[RVRPHVZHUHSXUL¿HGIURP
mice plasma. As shown in Figure 9a, mice treated with 
Curcumin, had smaller tumors than mice treated only 
Figure 7: a. Colony formation assay shows that Curcumin treatment caused a decrease of K562 and LAMA84 colonies 
area with respect to control cells. b.4XDQWLWDWLYHDQDO\VLVRIFRORQLHVDUHDRI.DQG/$0$FHOOVWUHDWHGZLWKDQGȝ0RI
Curcumin and/or transfected with miR-21 mimic and miR-21 inhibitor. c.(IIHFWRIDQGȝ0&XUFXPLQRQ.DQG/$0$FHOOV
PLJUDWLRQ&0/FHOOVZHUHDOVRFRWUHDWHGZLWKDQGȝ0&XUFXPLQDQG*:ȝ0IRUKRXUVValues are the mean ± SD of 
3 independent experiments *p p .
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with corn oil. Figure 9b shows the tumor size average 
LQ FRQWURO DQG WUHDWHGPLFH:HSXUL¿HG WKH H[RVRPHV
released in the plasma of mice treated with Curcumin and 
control. Real time PCR analysis indicated that exosomes 
released in the plasma of the treated mice were enriched in 
miR-21 with respect control mice (Figure 9c). Overall, 
WKHVHGDWDFRQ¿UPHGRXUK\SRWKHVLV WKDW WKHDQWLFDQFHU
effects of Curcumin may occur through the miR-21 
selective packaging in exosomes.
DISCUSSION
The understanding of the molecular basis of chronic 
myeloid leukemia development led to the synthesis 
RI ,PDWLQLE0HV\ODWH ,0 D KLJKO\ VSHFL¿F %UF$EO
tyrosine kinase inhibitor. Although a vast majority of 
patients with CML respond to IM, resistance might occur 
de novo or during treatment [30]. Resistance to IM or 
to the second, third generation of TKIs has attracted the 
DWWHQWLRQ RIPDQ\ UHVHDUFKHUV WR ¿QG QHZ WKHUDSLHV RU
different compounds to use as adjuvants for conventional 
therapy. In this work we investigated the antineoplastic 
effect of Curcumin in CML cells.
Curcuminoids are known to inhibit the tumor 
growth affecting the activity of multiple molecular 
targets involved in carcinogenesis. Curcumin exhibits its 
anticancer effects by regulating genes involved in cellular 
signaling pathways, including nuclear factor-kappa B, 
protein kinase B (AKT), mitogen-activated protein kinase 
(MAPK), p53, and other pathways [31].
In this study, we provide evidence that the 
effects of Curcumin may affect in vitro and in vivo 
malignant properties of CML cells and we suggest that 
these effects are mediated by a disposal of miR-21 in 
exosomes released by CML cells. In our previous paper, 
we demonstrated that LAMA84 cells release exosomes 
containing several miRNAs, differentially expressed 
compared to producing parental cells. We focused our 
attention on miR-126; LAMA84-exosomes were enriched 
in this angiomiR that was biologically active in endothelial 
cells. Other groups have also evidenced that miRNAs 
)LJXUHD%FU$EOH[SUHVVLRQLQ.DQG/$0$FHOOVWUHDWHGZLWKDQGȝ0RI&XUFXPLQIRUKRXUVZDV
determined by quantitative Real time PCR analysis. b. Western blot analysis of Bcr-Abl in K562 and LAMA84 cells treated with 
DQGȝ0RI&XUFXPLQIRUKRXUV$FWLQZDVXVHGDVORDGLQJFRQWURO0L5EOHYHOVLQ.c. and LAMA84 d. cells and their 
UHOHDVHGH[RVRPHVDIWHUWUHDWPHQWZLWKDQGȝ0RI&XUFXPLQIRUKRXUVZHUHGHWHUPLQHGE\TXDQWLWDWLYH5HDOWLPH3&5DQDO\VLV
Values are the mean ± SD of 3 independent experiments *p p 
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contained in the exosomes released by K562 cells, are able 
WRPRGXODWHFHOOFRPPXQLFDWLRQDQGLQÀXHQFHWKHJHQHWLF
changes within CML patients [32]. Recently, several 
studies have indicated that miRNAs may be considered 
a new class of oncogenes. These oncomirs induce tumor 
growth negatively regulating tumor suppressor genes. 
The modulation of oncomirs levels might represent an 
alternative strategy for cancer treatment.
Ostenfeld et al showed a possible advantage for 
cancer cells to eliminate tumor-suppressor miRNAs via 
exosomes; this mechanism may support the metastatic 
process. They demonstrated a selective pressure for 
disposal of miR-23b, which may contribute to the 
transcriptomic changes associated with a cellular 
metastatic state [10].
In other experimental setting, De Candia et al 
demonstrated that reduction of intracellular level of 
miR-150, a key regulator of mRNAs critical for 
lymphocyte differentiation and functions, via its selective 
release in the external milieu, may regulate gene 
expression during lymphocyte activation [33].
Now we hypothesized a novel role for exosome 
release as a route to cellular disposal of an oncogenic 
miRNAs, such as miR-21, as a consequence of Curcumin 
treatment. The miRNA-21 has been indicated as a 
miRNA overexpressed in several solid tumors; miR-21 is 
involved in a number of steps of tumor progression, such 
as proliferation, angiogenesis, antiapoptotic and response 
to chemotherapy. A number of miR-21 target genes have 
EHHQ LGHQWL¿HG LQFOXGLQJ37(13'&'DQG%7*
which play important roles in the oncogenic process 
[34]. It was demonstrated that decreased expression 
of miR-21 in human lung cancer cells by inhibition 
RI 12; 1$'3+ R[LGDVH UHGXFHV PHWDVWDVLV >@
Moreover the downregulation of miR-21 expression 
restrains non-small cell lung cancer cell proliferation 
and migration through upregulation of programmed cell 
death 4 protein [36].
)LJXUHD5HSUHVHQWDWLYHWXPRUPDVVHVUHPRYHGIURPPLFHWUHDWHGZLWKFRUQRLOFRQWURORUPJRI&XUFXPLQ 
b. Tumor masses size average of mice treated with corn oil (Ctrl) and mice treated with 2 mg of Curcumin. c. MiR-21 levels in exosomes 
collected from serum of control mice and mice treated with 2 mg of Curcumin were determined by quantitative Real time PCR analysis. 
Values are the mean ± SD of 3 independent experiments *pp DQGp
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Few studies have focused on the role of miR-21 in 
CML progression. Li et al demonstrated that anti-miR-21 
oligonucleotides (AMO-miR-21) sensitized K562 cells, 
to arsenic trioxide by inducing apoptosis. AMO-miR-21 
down-regulated mature miR-21 expression level and 
partially induced up-regulation of PDCD4 level [37]. 
Other groups demonstrated that antisense oligonucleotide 
against miR-21 inhibits migration and induces apoptosis 
in leukemic K562 cells [38].
Our results indicate that Curcumin might exert 
anticancer effects through elimination of miR-21, via 
exosomes. We showed that Curcumin caused a decrease 
of miR-21, but not pre-miR-21, in CML cells after 
Curcumin treatment. On the contrary, we observed an 
increase of miR-21 in the exosomes released by CML 
cells after addition of Curcumin (Figure 2). Our results 
are in line with other studies that demonstrated the effects 
of Curcumin on cancer cell survival through down-
regulation of miR-21 and increase of PTEN. PTEN up 
regulation, caused by non-genomic mechanisms, such 
as post transcriptional regulation by non-coding RNA, 
antagonizes the PI3K-AKT pathway [39]. This inhibitory 
effect acts on the PI-3K-AKT pathway, which controls cell 
proliferation and survival.
We found that the decrease of cellular miR-21, 
VLJQL¿FDQWO\ XSUHJXODWHG WKH H[SUHVVLRQ RI 37(1
(Figure 4) modulating the phosphorylation of AKT 
(Figure 5). Several studies also showed that Curcumin 
inhibited the phosphorylation of AKT, mTOR, and 
their downstream substrates. It was demonstrated that 
'LÀXRULQDWHG&XUFXPLQ &') >@DQRQWR[LFDQDORJ
of Curcumin modulated the expression of miR-21 and 
PTEN in pancreatic cancer and inhibited the growth 
of colon cancer cells [40]. From a functional point of 
view, an increase of PTEN and the consequent decrease 
of AKT phosphorylation caused an inhibition of cell 
survival, as we demonstrated by an in vitro colony 
formation assay (Figure 7). Our current data show an 
inverse relationship between miR-21 and PTEN and 
support the role of Curcumin on modulation of the PTEN 
expression, via a selective packaging of miR-21 in CML 
exosomes (Figure 10). PTEN also modulates VEGF 
expression, down-regulating PI3K/AKT pathway; forced 
expression of PI3K or AKT alone directly increased 
VEGF mRNA expression, suggesting that PI3K and AKT 
DUHVXI¿FLHQWWRUHJXODWH9(*)H[SUHVVLRQ)LJXUH
Angiogenesis in haematological malignancies is similar 
to that seen in solid tumors; secreted VEGF contributes 
to haematological disease progression by an autocrine or 
paracrine mechanism. VEGF signaling inhibition results in 
VLJQL¿FDQWWXPRUJURZWKGHOD\LQDZLGHUDQJHRIDQLPDO
models [41]. As shown by our results, Curcumin treatment 
caused a decrease of VEGF at mRNA and protein levels, 
in K562 and LAMA84 cells (Figure 6). Masuelli et al 
demonstrated in vivo the antitumor effects of Curcumin 
alone or in combination with resveratrol. The authors 
observed that the administration of Curcumin in Balb/c 
mice reduced the growth of the transplanted salivary 
gland cancer cells and this effect is potentiated by the 
combination of Curcumin and resveratrol [42].
Interestingly, we observed an opposite effects of 
Curcumin on the cellular level of miR-196b, a microRNA 
that was recently associated to CML development.
We observed that Curcumin caused an increase 
of miR-196b in CML cells and a decrease of its levels 
in the released exosomes, leading to a down regulation 
of Bcr-Abl levels in leukaemia cells. These results are in 
line with data showing that miR-196b targets BCR-ABL 
causing a decrease of oncogene expression at mRNA and 
protein level. Recent studies have indicated that miR-
196b inhibits cell proliferation and promotes apoptosis in 
B-cell ALL cells. The expression levels of miR-196b were 
VLJQL¿FDQWO\ORZHULQSDWLHQWVZLWK&0/WKDQLQKHDOWK\
controls [23].
Our in vivo experiments demonstrated that 
&XUFXPLQWUHDWHGDQLPDOVKDGDVLJQL¿FDQWUHGXFWLRQLQ
tumor growth as measured by the decrease in size of the 
subcutaneous xenografts compared to untreated animals. 
Figure 10: Working hypothesis of the effects of Curcumin on CML cells. Curcumin caused a decrease of cellular levels of 
miR-21 and a concomitant increase of its amount in exosomes. Reduced levels of miR-21 in CML cells induce PTEN expression and 
consequently a decrease of AKT phosphorylation and a down regulation of VEGF expression and release. Curcumin also induced the 
expression of miR-196b and consequently caused a reduction of Brc-Abl expression.
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Moreover, the amount of exosomes collected from plasma 
of treated mice was higher than control mice and these 
exosomes are enriched in miR-21 compared to control 
exosomes. Overall, these data indicated an antineoplastic 
role of Curcumin in CML cells, by a selective packaging 
of miR-21 in exosomes and an increase of miR-196b in 
CML cells suggesting that Curcumin could be a potential 
therapeutic agent for CML.
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